Remove Drugs Remove Pharma Companies Remove Research
article thumbnail

Indian healthcare providers and pharma companies speed up to combat TB as drug resistance concerns emerge

AuroBlog - Aurous Healthcare Clinical Trials blog

Indian healthcare providers and pharma companies pace up their efforts with early detection and research for new medicines to combat the spread of tuberculosis as drug resistance concerns emerge. TB is a significant public health threat, with an estimated 10 million annual cases. India shares the highest TB burden with 2.69

article thumbnail

Cloud robotics labs are accelerating drug discovery and development

Pharmaceutical Technology

Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development. Remote-controlled robotic labs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Roche buys into Alnylam heart drug in cardiovascular research bet

Bio Pharma Dive

The Swiss pharma company is the latest large drugmaker to invest big in an experimental heart treatment, after years of prioritizing medicines for cancer and immune diseases.

article thumbnail

Lilly backs a biotech's spinout and places a small bet on protein degradation

Bio Pharma Dive

An alliance with BeyondSpring spinout Seed Therapeutics makes Eli Lilly the latest pharma company to dive into the fast-emerging drug research field.

Protein 242
article thumbnail

Pfizer buys a private biotech and its RSV drug research

Bio Pharma Dive

The pharma company adds experimental RSV treatments to its pipeline through the deal, which is worth up to $525 million.

article thumbnail

How epilepsy researchers are moving the needle past anti-seizure treatments

Pharmaceutical Technology

While several therapeutics are available for treating symptoms associated with epilepsy, researchers and patients have strongly called out the need for more holistic treatments that would address the condition as a whole. Meanwhile, others are researching the link between gene variation and different responses to treatments.

Research 264
article thumbnail

Boehringer extends cancer dealmaking with right to buy biotech partner

Bio Pharma Dive

The German pharma company has secured an option to acquire Trutino Biosciences, two years after inking a research collaboration with the San Diego drug developer.